Drugs / (2R,6R)-hydroxynorketamine

Trials 4 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT04711005 Jan 2021 → Apr 2023 major depressive disorder National Institute of Mental Health (NIMH) Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT05864053 Sep 2024 → Dec 2026 expected neuropathy, painful Rush University Medical Center Recruiting No outcome recorded
Phase 22 trials
Phase 2 NCT07504601 Jul 2026 → Dec 2030 expected National Center for Complementary and Integrative Health (NCCIH) Not yet recruiting No outcome recorded
Phase 2 NCT06511908 Nov 2024 → Jul 2027 expected major depressive disorder National Institute of Mental Health (NIMH) Recruiting No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as (2R,6R)-hydroxynorketamine “This study will test whether a single dose of an experimental drug called (2R,6R)-hydroxynorketamine (HNK) can help reduce short term pain in healthy adults.” NCT07504601
4

NCT07504601

NCT06511908

NCT04711005

NCT05864053

Known as (2r,6r)-hnk ChEMBL registry synonym — accepted as the source's own label CHEMBL4650718
Known as (2r,6r)-hnk hydrochloride ChEMBL registry synonym — accepted as the source's own label CHEMBL4650718
Known as (2r,6r)-hydroxynorketamine hydrochloride ChEMBL registry synonym — accepted as the source's own label CHEMBL4650718
Known as HNK “Researchers want to know if a faster-acting drug, (2R,6R)-hydroxynorketamine (HNK), can better treat the symptoms of MDD.” NCT06511908
Known as HydroxyNorKetamine (HNK) “This study will test whether a single dose of an experimental drug called (2R,6R)-hydroxynorketamine (HNK) can help reduce short term pain in healthy adults.” NCT07504601
Modality Small molecule CHEMBL4650718
Route Intravenous “will be administered intravenously over a 40-minute period” NCT04711005